Recent advances on the role of microRNAs in both Insulin resistance and cancer

Current Pharmaceutical Design

Volumn 23, Issue 25, 2017, Pages 3658-3666

  Vivacqua, Adele ^a   De Marco, Paola ^a   Belfiore, Antonino ^b   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cancer; Insulin resistance; MiR 103 107; MiR 221 222; MiR 29; MiRNAs

Indexed keywords

CAVEOLIN; DICER; MICRORNA; MICRORNA 103; MICRORNA 107; MICRORNA 221; MICRORNA 222; MICRORNA 29; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

GENE ACTIVITY; GENE CLUSTER; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; INSULIN RESISTANCE; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; METABOLISM; NEOPLASM; PHYSIOLOGY; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INSULIN RESISTANCE; MICRORNAS; NEOPLASMS;

EID: 85033378972     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170622105123     Document Type: Review

References (211)

1. Djiogue S, Nwabo Kamdje AH, Vecchio L, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 2013; 20(1): R1-R17.
2. George S, Rochford JJ, Wolfrum C, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 2004; 304: 1325-8.
3. Zhande R, Mitchell JJ, Wu J, et al. Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1. Mol Cell Biol 2002; 22: 1016-26.
4. Aguirre V, Uchida T, Yenush L, et al. NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275: 9047-54.
5. Puig O, Tjian R. Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. Genes Lancet Dev 2000; 19: 2435-46.
6. Tsai S, Clemente-Casares X, Revelo X, et al. Are obesity-related insulin resistance and type 2 diabetes autoimmune diseases? Diabetes 2015; 64: 1886-97.
7. Lizunov VA, Stenkula KG, Lisinski I, et al. Insulin stimulates fusion, but not tethering, of GLUT4 vesicles in skeletal muscle of HA-GLUT4-GFP transgenic mice. Am J Physiol Endocrinol Metab 2012; 302: E950-60.
8. Wheatcroft SB, Williams IL, Shah AM, et al. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003; 20: 255-68.
9. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75 (3): 473-86.
10. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: e1369.
11. Campbell AW. The diabetes pandemic. Altern Ther Health Med 2011; 17: 8-9.
12. Hadaegh F, Mohebi R, Cheraghi L, et al. Do different metabolic syndrome definitions predict cerebrovascular events and coronary heart disease independent of their components? 9 years follow-up of the tehran lipid and glucose study. Stroke 2012; 43: 1669-71.
13. Vykoukal D, Davies MG. Biology of metabolic syndrome in a vascular patient. Vascular 2012; 20 (3): 156-65.
14. Kaidanovich-Beilin O, Cha DS, McIntyre RS. Crosstalk between metabolic and neuropsychiatric disorders. F1000 Biol Rep 2012; 4: 14.
15. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316-38.
16. Jeon CY, Haan MN, Cheng C, et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012; 35: 520-5.
17. Witso E. The role of infection-associated risk factors in prosthetic surgery. Hip Int 2012; 22 (8): S5-S8.
18. Byers T, Sedjo RL. Does intentional weight loss reduce cancer risk? Diabetes Obes Metab 2011; 13: 1063-72.
19. Spyridopoulos TN, Dessypris N, Antoniadis AG, et al. Insulin resistance and risk of renal cell cancer: a case-control study. Hormones 2012; 11: 308-15.
20. Malaguarnera R, Belfiore A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front in Endocrinol 2014; 5, 10: 1-15.
21. De Marco P, Romeo E, Vivacqua A, et al. GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. Endocrin Relat Cancer 2014; 21: 739-53
22. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch of Physiol and Biochem 2008; 114(1): 23-37
23. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiplephysio-logical functions for insulin-like growth factors. Physiol Rev 1996; 76: 1005-26.
24. Vigneri R, Goldfine ID, Frittitta L. Insulin, insulin receptors, and cancer. J Endocrinol Invest 2016.
25. Weichhaus M, Broom J, Wahle K, et al. A novel role for insulin resistance in the connection between obesity and postmenopausal breast cancer. Int J Oncol 2012; 41: 745-52.
26. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocrin Relat Cancer 2011; 18: R125-47.
27. Gunter MJ, Xie X, Xue X, et al. Breast cancer risk in metabolically healthy but overweight postmenopausal women. Cancer Res.2015; 75: 270-4.
28. Hernandez AV, Guarnizo M, Miranda Y, et al. Association between insulin resistance and breast carcinoma: a systematic review and meta-analysis. PLoS One 2014; 9: e99317.
29. Cohen DH, Le Roith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocrin Relat Cancer 2012; 19: F27-F45.
30. Sieri S, Muti P, Claudia A, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 2012; 130: 921-9.
31. Healy LA, Ryan AM, Carroll P, et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 2010; 22(4): 281-8.
32. De Marco P, Cirillo F, Vivacqua A, et al. Novel aspects concerning the functional cross-talk between the insulin/IGF-I system and estrogen signaling in cancer cells. Front Endocrinol 2015; 6 (30): 1-8.
33. Belfiore A, Frasca F, Pandini G, et al. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009; 30: 586-623.
34. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-69.
35. Seke Etet PF, Vecchio L, Nwabo Kamdje AH. Interactions between bone marrow stromal microenvironment and B-chronic lympho cytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways? Cell Signal 2012; 24: 1433-43.
36. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology 2011; 81 (1): 24-9.
37. Catsburg C, Gunter MJ, Chen C, et al. Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease. Cancer Res 2014; 74: 3248-58.
38. Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer 2012; 19: R225-41.
39. Burns KA, Korach KS. Estrogen receptors and human disease: an update. Arch Toxicol 2012; 86: 1491-504
40. Santolla MF, Avino S, Pellegrino M, et al. SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer. Cell Death Dis 2015 6: e1834.
41. De Francesco EM, Pellegrino M, Santolla MF, et al. GPER mediates activation of HIF1α/VEGF signaling by estrogens. Cancer Res 2014 Aug 1; 74(15): 4053-64.
42. Lappano R, De Marco P, De Francesco EM, et al. Cross-talk between GPER and growth factor signaling. J Steroid Biochem Mol Biol 2013; 137: 50-6.
43. Santolla MF, Lappano R, De Marco P, et al. G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17β-estradiol in cancer cells and cancer-associated fibroblasts. J Biol Chem 2012; 287: 43234-45.
44. Vivacqua A, Romeo E, De Marco P, et al. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Res Treat 2012; 133: 1025-35.
45. Albanito L, Madeo A, Lappano R, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007; 67: 1859-66.
46. Vivacqua A, Bonofiglio D, Recchia AG, et al. The G proteincoupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006; 20: 631-46.
47. Vivacqua A, Bonofiglio D, Albanito L, et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. Mol Pharmacol 2006; 70: 1414-23.
48. Maggiolini M, Vivacqua A, Fasanella G, et al. The G proteincoupled receptor GPR30 mediates c-fos upregulation by 17betaestradiol and phytoestrogens in breast cancer cells. J Biol Chem 2004; 279: 27008-16.
49. Mizukami Y. In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: from discovery to functions in vivo. Endocr J 2010; 57: 101-7.
50. Balhuizen A, Kumar R, Amisten S, et al. Activation of proteincoupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice. Mol Cell Endocrin 2010; 320: 16-24.
51. Liu S, Le May C, Wong WP, et al. Importance of extranuclear estrogen receptor-α and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 2009; 58: 2292-302.
52. Martensson UE, Salehi SA, Windahl S, et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiolstimulated insulin release in female mice. Endocrinology 2009; 150: 687-98.
53. Sharma G, Hu C, Brigman JL, et al. GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state. Endocrinology 2013; 154: 4136-45.
54. Gauthier BR, Wollheim CB. MicroRNAs: ‘ribo-regulators’ of glucose homeostasis. Nat Med 2006; 12: 36-8.
55. Hammond SM. MicroRNA therapeutics: A new niche for antisense nucleic acids. Trends Mol Med 2006; 12: 99-101.
56. Bartel, DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136: 215e233
57. Ban JJ, Lee M, Im W, et al. Low pH increases the yield of exosome isolation. Biochem Biophys Res Commun 2015; 461(1): 76-9.
58. Chevillet JR, Kang Q, Ruf IK, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci USA 2014; 111(41): 14888-93.
59. Sun T, Kalionis B, Lv G, et al. Role of exosomal noncoding RNAs in lung carcinogenesis. Biomed Res Int 2015: 125807.
60. Javidi MA, Ahmadi AH, Bakhshinejad B, Nouraee N, Babashah S, Sadeghizadeh M. Cell-free microRNAs as cancer biomarkers: the odyssey of miRNAs through body fluids. Med Oncol 2014; 31(12): 295.
61. Yang Y, Zhu R. Diagnostic value of circulating microRNAs for hepatocellular carcinoma. Mol Biol Rep 2014; 41(10): 6919-29.
62. Sorensen AE, Wissing ML, Salo S, et al. MicroRNAs Related to Polycystic Ovary Syndrome (PCOS). Genes (Basel) 2014; 5(3): 684-708.
63. Arrese M, Eguchi A, Feldstein AE. Circulating microRNAs: emerging biomarkers of liver disease. Semin Liver Dis 2015; 35(1): 43-54.
64. Delić D, Eisele C, Schmid R, et al. Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients. PLoS One 2016; 11(3): e0150154.
65. Barutta F, Tricarico M, Corbelli A, et al. Urinary exosomal microRNAs in incipient diabetic nephropathy. PLoS One 2013; 8(11): e73798.
66. Ortega FJ, Mercader JM, Catalan V, et al. Targeting the circulating microRNA signature of obesity. Clin Chem 2013; 59(5): 781-92.
67. Saj A, Lai EC. Control of microRNA biogenesis and transcription by cell signaling pathways. Curr Opin Genet Develop 2011; 21: 504e510.
68. Fabian MR, Sonenberg N. The mechanics of miRNA mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012; 19: 586e593.
69. Ha M, Kim VN Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15: 509-24.
70. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 2013; 14: 475-88.
71. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell 2008; 132: 9-14.
72. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-14.
73. Kim VN, Nam JW. Genomics of microRNA. Trends Genet 2006; 22: 165-73.
74. Chuang TY, Wu HL, Chen CC, et al. MicroRNA-223 expression is upregulated in insulin resistant human adipose tissue. J Diabetes Res 2015; 2015: 943659.
75. Wang L, Zhang N, Pan HP, et al. MiR-499-5p Contributes to hepatic insulin resistance by suppressing PTEN. Cell Physiol Biochem 2015; 36: 2357-65.
76. Wijesekara N, Zhang LH, Kang MH, et al. miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes 2012; 61: 653-58.
77. Dou L, Wang S, Sui X, et al. MiR-301a mediates the effect of IL-6 on the AKT/GSK pathway and hepatic glycogenesis by regulating PTEN expression. Cell Physiol Biochem 2015; 35: 1413-24.
78. Baroukh N, Ravier MA, Loder MK, et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem 2007; 282: 19575-88.
79. He A, Zhu L, Gupta N, et al. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 2007; 21: 2785-94.
80. Chakraborty C, Doss CG, Bandyopadhyay S, et al. Influence of miRNA in insulin signaling pathway and insulin resistance: micromolecules with a major role in type-2 diabetes. Wiley Interdiscip Rev RNA 2014; 5: 697-712.
81. Lu H, Buchan RJ, Cook SA. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res 2010; 86: 410-20.
82. Horie T, Ono K, Nishi H, et al. MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun 2009; 389: 315-20.
83. Zhou T, Meng X, Che H, et al. Regulation of Insulin resistance by multiple miRNAs via targeting the GLUT4 signalling Pathway. Cell Physiol Biochem 2016; 38: 2063-78.
84. Karolina DS, Armugam A, Tavintharan S, et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One 2011; 6(8): e22839.
85. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6(11): 857-66.
86. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6(4): 259-69.
87. Spizzo R, Nicoloso MS, Croce CM, et al. MicroRNAs in Cancer. Cell 2009; 137(3): 586-e1.
88. Gebeshuber CA, Zatloukal K, Martinez J, et al. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009; 10: 400e405.
89. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805e15810.
90. Liu B, Wu X, Liu B, et al. MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta 2012; 1822: 1692e1704.
91. Huse JT, Brennan C, Hambardzumyan D, et al. The PTENregulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009; 23(11): 1327-37.
92. Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137(6): 1005-17
93. Zhang LY, Ho-Fun Lee V, Wong AM, et al. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis 2013; 34: 454-63.
94. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al. Differential expression of miRNA-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol 2011; 46: 1391-402.
95. Akiyoshi S, Fukagawa T, Ueo H, et al. Clinical significance of miRNA-144-ZFX axis in disseminated tumor cells in bone marrow in gastric cancer cases. Br J Cancer 2012; 107: 1345-53.
96. Namlos HM, Meza-Zepeda LA, Baroy T, et al. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoSOne 2012; 7: e48086.
97. Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer 2009; 48: 615-23.
98. Vivacqua A, De Marco P, Santolla MF, et al. Estrogenic GPER signaling regulates miR-144 expression in cancer cells and cancerassociated fibroblasts (CAFs). Oncotarget 2015; 6(18): 16573-87.
99. Mourelatos Z, Dostie J, Paushkin S, et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev 2002; 16(6): 720-8.
100. Rottiers V, Naar AM. MicroRNAs in Metabolism and Metabolic Disorders. Nat Rev Mol Cell Biol 2014; 13(4): 239-50.
101. Wilfred BR, Wang WX, Nelson PT. Energizing miRNA research: A review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab 2007; 91: 209-17.
102. Vienberg S, Geiger J, Madsen S, et al. MicroRNAs in metabolism. Acta Physiol (Oxf) 2016 Mar 24.
103. Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011; 474: 649-53.
104. Naar AM. MiRs with a sweet tooth. Cell Metab 2011; 14: 149-50.
105. Vatandoost N, Amini M, Iraj B, et al. Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats. Gene 2015; 572(1): 95-100.
106. Bhatia H, Pattnaik BR, Datta M. Inhibition of mitochondrial β-oxidation by miR-107 promotes hepatic lipid accumulation and impairs glucose tolerance in vivo. Int J Obes (Lond) 2016; 40(5): 861-9.
107. Martello G, Rosato A, Ferrari F, et al. A MicroRNA targeting Dicer for metastasis control. Cell 2010; 141: 1195-207.
108. Foley NH, O’Neill LA. miR-107: a Toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes. J Leuk Biol 2012; 92 (3): 521-7.
109. Stralfors P. Caveolins and caveolae, roles in insulin signalling and diabetes. Adv Exp Med Biol 2012; 729: 111-26.
110. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8: 185-94.
111. Anwar SL, Wahyono A, Aryandono T, et al. Caveolin-1 in breast cancer: single molecule regulation of multiple key signaling pathways. Asian Pac J Cancer Prev 2015; 16(16): 6803-12.
112. Pucci M, Bravata V, Forte GI, et al. Caveolin-1, Breast Cancer and Ionizing Radiation. Cancer Genom Proteomics 2015; 12: 143-52.
113. Xu Q, Yao M, Chen Li. MicroRNAs 103 and 107: potential molecular links between diabetes and cancer. Chin Med J 2013; 126 (13): 2553-5.
114. Mercier I, Lisanti MP. Caveolin-1 and breast cancer: a new clinical perspective. Adv Exp Med Biol 2012; 729: 83-94.
115. Shi XY, Xiong LX, Xiao L, et al. Downregulation of caveolin‑1 upregulates the expression of growth factors and regulators in co‑culture of fibroblasts with cancer cells. Mol Med Rep 2016 Jan; 13(1): 744-52.
116. Chen WS, Liu LC, Yen CJ, et al. Nuclear IKKα mediates microRNA-7/-103/107/21 inductions to downregulate maspin expression in response to HBx overexpression. Oncotarget 2016 Jul 7.
117. Xiao LS, Zou XJ, Hu W, et al. Expression of microRNA-107 in hepatocellular carcinoma and its clinical significance Nan Fang Yi Ke Da Xue Xue Bao 2016; 36(7): 974-8.
118. Zhang L, Ma P, Sun LM, et al. MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer. Mol Carcinog 2016; 55(5): 768-77.
119. Xia W, Ni J, Zhuang J, et al. MiR-103 regulates hepatocellular carcinoma growth by targeting AKAP12. Int J Biochem Cell Biol 2016; 71: 1-11.
120. Kleivi Sahlberg K, Bottai G, Naume B, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res 2015; 21(5): 1207-14.
121. Chen Z, Lai TC, Jan YH, et al. Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. J Clin Invest 2013; 123(3): 1057-67.
122. Ayremlou N, Mozdarani H, Mowla SJ, et al. Increased levels of serum and tissue miR-107 in human gastric cancer: Correlation with tumor hypoxia. Cancer Biomark 2015; 15(6): 851-60.
123. Chen HY, Lin YM, Chung HC, et al. miR-103/107 promotes metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 2012; 72(14): 3631-41.
124. Inbal B, Cohen O, Polak-Charcon S, et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390: 180-4.
125. Gozuacik D, Kimchi A. DAPK protein family and cancer. Autophagy 2006; 2: 74-9.
126. Nagata T, Shimada Y, Sekine S, et al. Prognostic significance of NANOG and KLF4 for breast cancer. Breast Cancer 2014; 21(1): 96-101.
127. Zhang JJ, Wang CY, Hua L, et al. miR-107 promotes hepatocellular carcinoma cell proliferation by targeting Axin 2. Int J Clin Exp Pathol 2015; 8(5): 5168-74.
128. Geng L, Sun B, Gao B, et al. MicroRNA-103 Promotes Colorectal Cancer by Targeting Tumor Suppressor DICER and PTEN. Int J Mol Sci 2014; 5: 8458-72.
129. Sahasrabuddhe NA, Huang TC, Kumar P, et al. Ablation of Dicer leads to widespread perturbation of signaling pathways. Biochem Biophys Res Commun 2015; 463(3): 389-94.
130. Zampetaki A, Mayr M. Sweet Dicer. Impairment of Micro-RNA processing by diabetes. Circ Res 2015; 117: 116-8.
131. Yan Y, Salazar TE, Dominguez II JM, et al. Dicer Expression Exhibits a Tissue-Specific Diurnal Pattern That Is Lost during Aging and in Diabetes. PLoS ONE 2013; 8(11): e80029.
132. Khoshnaw SM, Rakha EA, Abdel-Fatah TM, et al. Loss of Dicer expression is associated with breast cancer progression and recurrence. Breast Cancer Res Treat 2012; 135: 403-13.
133. Jho EH, Zhang T, Domon C, et al. Wnt beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002; 22: 1172-83.
134. Wei Z, Zhong M, Guo Y, et al. Original papers Expression of β-catenin and AXIN2 in ameloblastomas. Contemp Oncol (Pozn) 2013; 17(3): 250-6.
135. Koinuma K, Yamashita Y, Liu W, et al. Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability. Oncogene 2005; 25: 139-46.
136. Karczewska-Kupczewska M, Stefanowicz M, Matulewicz N, et al. Wnt signaling genes in adipose tissue and skeletal muscle of humans with different degrees of insulin sensitivity. J Clin Endocrinol Metab 2016; 101(8): 3079-87.
137. Peyrou M, Bourgoin L, Foti M. PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer. Dig Dis 2010; 28: 236-46.
138. Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008; 16: 1289-300.
139. Nelson OL, Jansen HT, Galbreath E, et al. Grizzly bears exhibit augmented insulin sensitivity while obese prior to a reversible insulin resistance during hibernation. Cell metabolism 2014; 20(2): 376-82.
140. Pal A, Barber TM, Van de Bunt M, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. The New England journal of medicine 2012; 367(11): 1002-11.
141. Bulger DA, Conley J, Conner SH, et al. Role of PTEN in TNF induced insulin resistance. Biochem Biophys Res Commun 2015; 461(3): 533-6.
142. Xie Y, Naizabekov S, Chen Z, et al. Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes (Review). Oncology Letters 2016; 12: 375-8.
143. Gustafson S, Zbuk KM, Scacheri C et al. Cowden syndrome. Semin Oncol 2007; 34: 428-34.
144. Hodakoski C, Hopkins BD, Barrows D et al. Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis. Proc Natl Acad Sci USA 2014; 111(1): 155-60.
145. Zhang LL, Liu J, Lei S et al. PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression. Cell Signal 2014; 26: 1011-20.
146. Chistiakov DA, Sobenin IA, Orekhov AN, et al. Human miR-221 and miR-222 in Physiological and Atherosclerotic Vascular Remodeling. Biomed Res Int 2015; 2015: 354517.
147. Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221 and miR-222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia 2012; 17(1): 65-77.
148. Leung A, Trac C, Jin W, et al. Novel long noncoding RNAs are regulated by angiotensin II in vascular smoothmuscle cells. Circulation Research 2013; 113 (3): 266-78.
149. Di Leva G, Gasparini P, Piovan C, et al. MicroRNA cluster 221-222 and estrogen receptor _ interactions in breast cancer. J Natl Cancer Inst 2010; 102(10): 706-21
150. Matsuzaki J, Suzuki H. Role of MicroRNAs-221/222 in digestive systems. J Clin Med 2015; 4(8): 1566-77.
151. Meerson A, Traurig M, Ossowski V, et al. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Diabetologia 2013; 56: 1971-9.
152. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
153. Lustig Y, Barhod E, Ashwal-Fluss R, et al. RNA-binding protein PTB and microRNA-221 coregulate AdipoR1 translation and adiponectin signaling. Diabetes 2014; 63(2): 433-45.
154. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9
155. Lustig Y, Hemi R, Kanety H. Regulation and function of adiponectin receptors in skeletal muscle. Vitam Horm 2012; 90: 95-123
156. Di Martino MT, Rossi M, Caracciolo D, et al. MiR-221 and miR-222 are promising targets for innovative anticancer therapy. Expert Opin Ther Targets 2016; 21: 1-10.
157. Lu X, Zhao P, Zhang C, et al. Analysis of miR-221 and p27 expression in human gliomas. Mol Med Report 2009; 2(4): 651-6.
158. Veerla S, Lindgren D, Kvist A, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 2009; 124(9): 2236-42.
159. Radojicic J, Zaravinos A, Vrekoussis T, et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10(3): 507-17.
160. Galardi S Mercatelli N, Giorda E, et al. MiR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem 2007; 282: 23716-24.
161. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27(43): 5651-61.
162. Sarkar S, Dubaybo H, Ali S, et al. Down-regulation of mir-221 inhibits proliferation of pancreatic cancer cells through upregulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res 2013; 3: 465-77.
163. Zhang J, Han L, Ge Y, et al. miR-221 and miR-222 promote malignant progression of glioma through activation of the Akt pathway. Int. J. Oncol 2010; 36(4): 913-20.
164. Quintavalle C, Garofalo M, Zanca C, et al. miR-221 and miR-222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP[mu]. Oncogene 2011
165. Mari E, Zicari A, Fico F, et al. Action of HMGB1 on miR-221 and miR-222 cluster in neuroblastoma cell lines. Oncol Lett 2016; 12(3): 2133-8.
166. Yang W, Yang Y, Xia L, et al. MiR-221 Promotes Capan-2 Pancreatic Ductal Adenocarcinoma Cells Proliferation by Targeting PTEN-Akt. Cell Physiol Biochem 2016; 38: 2366-74.
167. Chen X, Liu J, Song Y, et al. MicroRNAs 221/222 and genisteinmediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila) 2011; 4(1): 76-86.
168. Yang Y, Zhao X, Li H-X. MiR-221 and miR-222 simultaneously target ARID1A and enhance proliferation and invasion of cervical cancer cells Europ Review Med Pharmacol Sciences 2016; 20: 1509-15.
169. Cochrane DR, Cittelly DM, Howe EN, et al. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer 2010; 1(6): 306-19.
170. Pan Y, Li J, Zhang Y, et al. Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression. Sci. Rep 2016; 6: 25798.
171. Garofalo M, Quintavalle C, Romano G, et al. miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy. Curr Mol Med 2012; 12(1): 27-33.
172. Amodio N, Rossi M, Raimondi L, et al. miR-29s: a family of epimiRNAs with therapeutic implications in hematologic malignancies Oncotarget 2015; 6(15): 12837-61
173. Kriegel AJ, Liu Y, Fang Y, et al. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012; 44: 237-44.
174. Kollinerova S, Vassanelli S, Modriansky M. The role of miR-29 family members in malignant hematopoiesis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014; 158(4): 489-501.
175. Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element directs microRNA nuclear import. Science 2007; 315: 97-100.
176. Kole AJ, Swahari V, Hammond SM, et al. miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis. Genes Dev 2011; 25: 125-30.
177. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027-32.
178. Han YC, Park CY, Bhagat G, et al. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med 2010; 207: 475-89.
179. Martinez I, Cazalla D, Almstead LL, et al. miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci USA 2011; 108: 522-7.
180. Ma F, Xu S, Liu X, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-g. Nat Immunol 2011; 12: 861-9.
181. Ślusarz A, Pulakat L. The two faces of miR-29. J Cardiovasc Med (Hagerstown) 2015; 16(7): 480-90.
182. Bagge A, Clausen TR, Larsen S, et al. MicroRNA-29a is upregulated in beta-cells by glucose and decreases glucose-stimulated insulin secretion. Biochem Biophys Res Commun 2012; 426: 266-72.
183. Baran-Gale J, Fannin EE, Kurtz CL, et al. Beta cell 59-shifted isomiRs are candidate regulatory hubs in type 2 diabetes. PLoS One 2013; 8: e73240.
184. Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab 2013; 17: 20233.
185. Kurtz CL, Peck BCE, Fannin EE, et al. MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes 2014; 63: 3141-8.
186. Fiserova B, Kubiczkova L, Sedlarikova L, Hajeka R, Sevcikova S. The miR-29 family in hematological malignancies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159(2): 184-91.
187. Suzuki H, Saito Y, Hibi T. MicroRNAs in Gastric Cancer. Springer, New York, 2011.
188. Ding DP, Chen ZL, Zhao XH, et al. miR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression. Carcinogenesis 2011; 32: 1025-32.
189. Meng XZ, Zheng TS, Chen X, et al. microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells. J Gastroenterol Hepatol 2011; 26: 186-193.
190. Xiong YJ, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-45.
191. Wu Q, Wang C, Lu ZH, et al. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta 2012; 413: 1058-65.
192. Pass HI, Goparaju C, Ivanov S, et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 2010; 70: 1916-24.
193. Fang C, Zhu DX, Dong HJ, et al: Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol 2012; 91: 553-59.
194. Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113: 6411-8.
195. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127: 118-26.
196. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol 2012; 36: E61-E67.
197. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009; 10: 400-5.
198. Sun XJ, Liu BY, Yana S, et al. MicroRNA-29a Promotes Pancreatic Cancer Growth by Inhibiting Tristetraprolin. Cell Physiol Biochem 2015; 37: 707-18.
199. Jiang H, Zhang G, Wu JH, et al. Diverse roles of miR-29 in cancer (Review). Oncology Reports 2014; 31: 1509-16.
200. Nagano H, Tomimaru Y, Eguchi H, et al. MicroRNA-29a induces resistance to gemcitabine through the Wnt/beta-catenin signaling pathway in pancreatic cancer cells. Int J Oncol 2013; 43: 1066-72.
201. Pei YF, Lei Y, Liu XQ. Mir-29a promotes cell proliferation and EMT in breast cancer by targeting ten eleven translocation 1. Biochim Biophys Acta 2016; S0925-4439 (16): 30211-13.
202. Cui Y, Li T, Yang D, et al. miR-29 regulates Tet1 expression and contributes to early differentiation of mouse ESCs. Oncotarget 2016.
203. Wang J, Xu J, Fu J, et al. MiR-29a Regulates Radiosensitivity in Human Intestinal Cells by Targeting PTEN Gene. Radiat Res 2016
204. Shen H, Li L, Yang S, et al. MicroRNA-29a contributes to drugresistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway. Gene 2016; 593(1): 84-90.
205. Shu D, Li H, Shu Y, et al. Systemic delivery of Anti-miRNA for suppression of triple negative breast cancer utilizing RNA Nanotechnology. ACS Nano 2015; 9(10): 9731-40.
206. Wang D, Shanina I, Toyofuku WM, et al. Inhibition of Autoimmune Diabetes in NOD Mice by miRNA Therapy PLoS One 2015; 10(12): e0145179.
207. Stenvang J, Petri A, Lindow M, et al. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012; 3: 1.
208. Kwekkeboom RF, Sluijter JP, van Middelaar BJ, et al. Increased local delivery of antagomir therapeutics to the rodent myocardium using ultrasound and microbubbles. J Control Release 2016; 222: 18-31.
209. Chen Y, Gao Y, Zhang K, et al. MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer. Cell Physiol Biochem 2015; 37(5): 1869-80.
210. Janssen EAM, Ovestad IT, Skaland I, et al. LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer. Cell Oncol 2009; 31(5): 335-43.
211. Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug. J Cell Biol 2012; 199(3): 407-12.